Developer docs
API playgroundTry for free, no card

Search company profiles

CellFE

Full company profile

uuid0000aaj

Namestring
CellFE
Legal namestring
CellFE, Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

CellFE is a privately held, venture-backed biotechnology company headquartered in Alameda, California, developing microfluidics-based instrumentation for non-viral gene delivery in cell therapy manufacturing. The company's core technology, branded as the Ryva Mechanoporation System (formerly Infinity MTx), uses a proprietary Volume Exchange for Convective Transfection (VECT) approach in which cells flow through microfluidic channels under chevron-shaped ridges, undergoing rapid compression and re-expansion that drives payload delivery in less than 10 milliseconds. CellFE claims >90% cell viability, payload delivery capability above 10 kb, and 1-2 day manufacturing processes across T cell, HSC, and iPSC workflows, with scalability from 1 million to billions of cells achieved by parallelizing channels.

The product platform consists of three commercial offerings: the Ryva Mechanoporation System benchtop instrument, Ryva PUPs single-use consumable processing units (recurring revenue), and the T-Rest kit launched in January 2025 for resting T cell CAR-T workflows. A High Volume Cyva System for clinical-scale manufacturing is in development through a partnership with CDMO Made Scientific. The company holds seven granted US patents plus international patents in China and Japan. Revenue is generated through direct enterprise sales of capital instruments and recurring consumables to pharmaceutical and biotechnology customers developing CAR-T, HSC, and iPSC-based therapies.

CellFE has raised approximately $22 million in a September 2023 Series A led by M Ventures (Merck KGaA's corporate venture arm), supplemented by $3.6 million in seed funding (2020) and a $1.19 million CIRM award (January 2025), for total disclosed funding of roughly $26.8 million. The company employs 11-50 staff, distributes primarily through direct sales and conference engagement (ISCT, ASGCT, BIO, Advanced Therapies Week), and has signed strategic collaborations with Made Scientific, DKFZ/TcellTech, and NIIMBL-funded consortia including Georgia Tech, Celgene, Merck, and the University of Iowa.

Short descriptiontext

CellFE is a private Alameda, California biotech that develops microfluidics-based, non-viral gene-delivery instruments (Ryva Mechanoporation System) and single-use consumables for cell therapy developers manufacturing CAR-T, HSC, and iPSC-based therapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAlameda, United States
HQ citystring
Alameda
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, microfluidic gene editing, non-viral transfection, cell engineering platform, CAR-T manufacturing tools
Industry1 code
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Services-Commercial Physical & Biological Research8731
Product category
Cell Therapy Manufacturing Equipment
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Ryva System Instruments
TypeHardware Sales
Description

Sale of benchtop instruments for microfluidic cell engineering. The Ryva Mechanoporation System is a compact device that can be used in biological safety cabinets or on laboratory benches.

cellfebiotech.com
2Ryva PUPs (Processing Units)
TypeSubscription Recurring
Description

Recurring sales of single-use consumable processing units. Each PUP contains eight single-use processing units and is designed for one-time use in the Ryva instrument.

cellfebiotech.com
3T-Rest Kit
TypeHardware Sales
Description

First-in-class resting T cell kit for CAR-T cell therapy manufacturing workflows. Sold as a product for cell therapy manufacturers.

cellfebiotech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Ryva™ System
Description

Benchtop instrument utilizing microfluidics-based technology for gene-editing payload delivery

cellfebiotech.com
+3 more records
Core offering1 text field

CellFE develops and sells a microfluidics-based, non-viral cell engineering platform for cell therapy manufacturing. The flagship Ryva Mechanoporation System is a benchtop instrument that uses rapid cellular compression via microfluidic channels with chevron-shaped ridges to deliver gene-editing payloads (including payloads above 10 kb) into T cells, HSCs, and iPSCs. The platform is sold together with single-use consumable Ryva PUPs and complementary workflow kits such as T-Rest for resting T cell CAR-T manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • >90% cell viability with superior cell health and functionality
+6 more records
Product overview1 text field

CellFE offers a microfluidics-based cell engineering platform centered on the Ryva™ Mechanoporation System, a benchtop instrument that uses non-viral gene delivery technology for cell therapy manufacturing. The platform includes Ryva™ PUPs (single-use processing unit consumables) and the T-Rest resting T cell kit for specialized CAR-T workflows. The technology, originally branded as Infinity MTx, leverages rapid cellular compression through microfluidic channels to enable complex genome editing with superior cell health and scalability from millions to billions of cells. Key capabilities include >90% viability, delivery of payloads >10kb, 1-2 day manufacturing processes, and no requirement for viral vectors.

Product and service4 records
1Ryva Mechanoporation System
CategoryCapital equipment / cell engineering instrument
Description

Benchtop instrument utilizing novel microfluidics-based mechanoporation technology to deliver a wide range of gene-engineering payload types and sizes into cells. Features small footprint suitable for biological safety cabinets, processing in under 10 milliseconds, intuitive software, up to 8 samples per run, and barcode reader plus NFC tag for run history analysis. Sold to pharmaceutical and biotechnology cell therapy developers and manufacturers.

2Ryva PUPs (Processing Units)
CategoryConsumables
Description

Single-use microfluidic processing units designed for use with the Ryva Mechanoporation System. Each PUP contains eight single-use processing units with capacity up to 2 x 10^6 cells per unit, providing a recurring consumable revenue stream tied to cell therapy manufacturing volumes.

3T-Rest (Resting T Cell Kit)
CategorySpecialized workflow kit / media
Description

First-in-class cell manufacturing transfection media product designed for resting (quiescent) T cell workflows. Enables efficient editing of resting T cells while preserving stem cell memory for more durable CAR-T cell treatments and reducing risk of chromosomal abnormalities in non-dividing cells.

4High Volume Cyva System
CategoryCapital equipment / clinical-scale system
Description

High-volume version of the Cyva system designed for clinical-scale non-viral gene editing of activated and resting T cell therapies, supporting scalable manufacturing workflows beyond research scale.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-13
Description

Strategic collaboration to generate pilot data on the CellFE High Volume Cyva System for T cell therapies. Made Scientific, a cell therapy CDMO, will conduct pilot-scale studies using CellFE's technology. The partnership aims to validate clinical-scale performance for both activated and resting T cell therapy manufacturing workflows, combining non-viral and viral gene editing approaches.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-30
Description

Strategic collaboration combining CellFE's Ryva Mechanoporation System with TcellTech's nanoSMAR gene expression DNA vector platform. Aims to advance personalized cell therapy development by addressing challenges in efficient DNA delivery and maintaining cell viability. Early results demonstrate strong compatibility with promising outcomes in generating stable cell lines expressing CARs or TCRs.

3Mike Rice
Strategic tierCoreTypeOthersAnnounced on2024-06-25
Description

Life science tools veteran appointed to Board of Directors. Previously served as Chairman & CEO at BioLife Solutions. Brings experience in scaling up life sciences tool businesses and deep expertise in CGT space.

cellfebiotech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

NIIMBL-funded project collaboration focused on scalable microfluidics for delivery of large transgenes to therapeutic cells. Project involves T-cells and iPSCs for cell therapy manufacturing, aiming to provide the first non-viral platform for transgene transfection from bench to final product using a single protocol.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Participant in NIIMBL-funded project (Project Call 2.2) for scalable microfluidics research. Contributing to development of non-viral platform for transgene transfection in cell product manufacturing.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Participant in NIIMBL-funded project (Project Call 2.2) for scalable microfluidics research. Contributing to development of GMP-compliant, scalable microfluidic method for transgene delivery.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Participant in NIIMBL-funded project for scalable microfluidics research. Part of consortium developing non-viral platform for cell therapy manufacturing.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MaxCyte is the dominant supplier of flow electroporation technology for non-viral gene delivery in cell therapy development, used by leading CAR-T developers including CRISPR Therapeutics. Directly competes with CellFE's mechanoporation platform as the primary alternative for ex-viral payload delivery into T cells, HSCs, and iPSCs.

TypeEmerging player
Description

Kytopen develops a Flowfect microfluidic platform for continuous, non-viral cell engineering with a similar design philosophy to CellFE's mechanoporation approach. Both target the same limitation of electroporation (cell stress) using microfluidic-based delivery, making Kytopen a direct emerging competitor.

TypeDirect peer
Description

Celetrix provides electroporation systems specifically tuned for primary and difficult-to-transfect cells including T cells, HSCs, and iPSCs. Competitor in the same gene-delivery tool category as CellFE, with overlapping target customers in cell therapy development.

TypeBroad incumbent
Description

Through its Cell Therapy Systems business (including the CTS Rotea counterflow centrifugation system), Thermo Fisher is a broad incumbent in cell therapy manufacturing tools serving the same developers targeted by CellFE. CellFE competes for share within a wider portfolio customer base.

TypeBroad incumbent
Description

Miltenyi Biotec offers a comprehensive suite of cell therapy manufacturing platforms, reagents, and instruments (CliniMACS, MACS, electroporation). Serves the same cell therapy developers as CellFE with a broader tools portfolio rather than specialization in delivery technology.

6Porton Biologics / Portal Biotechnologies
TypeEmerging player
Description

Portal Biotechnologies develops its own non-viral delivery platform for engineered cell therapy manufacturing, positioning it as an emerging competitor in the same microfluidic/physical delivery category as CellFE.

TypeBroad incumbent
Description

Lonza is a leading CDMO and process development partner for cell and gene therapy developers. While it doesn't directly compete with CellFE's delivery instrument, its process services touch overlapping buyer personas and could either partner with or compete for cell therapy developer budgets.

TypeBroad incumbent
Description

BioLife Solutions is a public CGT tools company specializing in biopreservation and cell processing consumables (CryoStor, ViaCell, ThawSTAR). Its board connection (Mike Rice is now on CellFE's board) and overlapping customer base create thematic peer comparability in CGT tools.

TypeBroad incumbent
Description

Cytiva (Danaher) provides bioprocessing and cell therapy manufacturing equipment and consumables, including cell processing instrumentation. Adjacent competitor to CellFE in cell therapy manufacturing tooling across upstream and downstream workflows.

TypeOthers
Description

Akadeum provides buoyancy-based cell separation technology used in cell therapy manufacturing workflows. While not directly competing with CellFE's delivery platform, it serves adjacent process steps within the same cell therapy developer buyer personas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CellFE

Cell Therapy Manufacturing Equipmentcellfebiotech.com

CellFE is a private Alameda, California biotech that develops microfluidics-based, non-viral gene-delivery instruments (Ryva Mechanoporation System) and single-use consumables for cell therapy developers manufacturing CAR-T, HSC, and iPSC-based therapies.

What CellFE does

CellFE is a privately held, venture-backed biotechnology company headquartered in Alameda, California, developing microfluidics-based instrumentation for non-viral gene delivery in cell therapy manufacturing. The company's core technology, branded as the Ryva Mechanoporation System (formerly Infinity MTx), uses a proprietary Volume Exchange for Convective Transfection (VECT) approach in which cells flow through microfluidic channels under chevron-shaped ridges, undergoing rapid compression and re-expansion that drives payload delivery in less than 10 milliseconds. CellFE claims >90% cell viability, payload delivery capability above 10 kb, and 1-2 day manufacturing processes across T cell, HSC, and iPSC workflows, with scalability from 1 million to billions of cells achieved by parallelizing channels.

The product platform consists of three commercial offerings: the Ryva Mechanoporation System benchtop instrument, Ryva PUPs single-use consumable processing units (recurring revenue), and the T-Rest kit launched in January 2025 for resting T cell CAR-T workflows. A High Volume Cyva System for clinical-scale manufacturing is in development through a partnership with CDMO Made Scientific. The company holds seven granted US patents plus international patents in China and Japan. Revenue is generated through direct enterprise sales of capital instruments and recurring consumables to pharmaceutical and biotechnology customers developing CAR-T, HSC, and iPSC-based therapies.

CellFE has raised approximately $22 million in a September 2023 Series A led by M Ventures (Merck KGaA's corporate venture arm), supplemented by $3.6 million in seed funding (2020) and a $1.19 million CIRM award (January 2025), for total disclosed funding of roughly $26.8 million. The company employs 11-50 staff, distributes primarily through direct sales and conference engagement (ISCT, ASGCT, BIO, Advanced Therapies Week), and has signed strategic collaborations with Made Scientific, DKFZ/TcellTech, and NIIMBL-funded consortia including Georgia Tech, Celgene, Merck, and the University of Iowa.

CellFE firmographics

Firmographics
Name
CellFE
Legal name
CellFE, Inc.
Website
https://cellfebiotech.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
CellFE is a private Alameda, California biotech that develops microfluidics-based, non-viral gene-delivery instruments (Ryva Mechanoporation System) and single-use consumables for cell therapy developers manufacturing CAR-T, HSC, and iPSC-based therapies.
Ownership category
akta.pro rank

CellFE industry classification

Industry
Product category
Cell Therapy Manufacturing Equipment
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy manufacturing
  • Microfluidic gene editing
  • Non-viral transfection
  • Cell engineering platform
  • CAR-T manufacturing tools

Where CellFE is headquartered

Location

Headquarters

HQ city
Alameda
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CellFE business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Ryva System Instruments: Sale of benchtop instruments for microfluidic cell engineering. The Ryva Mechanoporation System is a compact device that can be used in biological safety cabinets or on laboratory benches.
  2. Ryva PUPs (Processing Units): Recurring sales of single-use consumable processing units. Each PUP contains eight single-use processing units and is designed for one-time use in the Ryva instrument.
  3. T-Rest Kit: First-in-class resting T cell kit for CAR-T cell therapy manufacturing workflows. Sold as a product for cell therapy manufacturers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

CellFE product offering

Product offering

Core offering

CellFE develops and sells a microfluidics-based, non-viral cell engineering platform for cell therapy manufacturing. The flagship Ryva Mechanoporation System is a benchtop instrument that uses rapid cellular compression via microfluidic channels with chevron-shaped ridges to deliver gene-editing payloads (including payloads above 10 kb) into T cells, HSCs, and iPSCs. The platform is sold together with single-use consumable Ryva PUPs and complementary workflow kits such as T-Rest for resting T cell CAR-T manufacturing.

Product overview

CellFE offers a microfluidics-based cell engineering platform centered on the Ryva™ Mechanoporation System, a benchtop instrument that uses non-viral gene delivery technology for cell therapy manufacturing. The platform includes Ryva™ PUPs (single-use processing unit consumables) and the T-Rest resting T cell kit for specialized CAR-T workflows. The technology, originally branded as Infinity MTx, leverages rapid cellular compression through microfluidic channels to enable complex genome editing with superior cell health and scalability from millions to billions of cells. Key capabilities include >90% viability, delivery of payloads >10kb, 1-2 day manufacturing processes, and no requirement for viral vectors.

Differentiator

Problem solved

Functional benefit

Brands

  • Ryva™ System: Benchtop instrument utilizing microfluidics-based technology for gene-editing payload delivery
  • Ryva™ PUPs
  • T-Rest
  • Infinity MTx System

Products and services

  • Ryva Mechanoporation System Benchtop instrument utilizing novel microfluidics-based mechanoporation technology to deliver a wide range of gene-engineering payload types and sizes into cells. Features small footprint suitable for biological safety cabinets, processing in under 10 milliseconds, intuitive software, up to 8 samples per run, and barcode reader plus NFC tag for run history analysis. Sold to pharmaceutical and biotechnology cell therapy developers and manufacturers.
  • Ryva PUPs (Processing Units) Single-use microfluidic processing units designed for use with the Ryva Mechanoporation System. Each PUP contains eight single-use processing units with capacity up to 2 x 10^6 cells per unit, providing a recurring consumable revenue stream tied to cell therapy manufacturing volumes.
  • T-Rest (Resting T Cell Kit) First-in-class cell manufacturing transfection media product designed for resting (quiescent) T cell workflows. Enables efficient editing of resting T cells while preserving stem cell memory for more durable CAR-T cell treatments and reducing risk of chromosomal abnormalities in non-dividing cells.
  • High Volume Cyva System High-volume version of the Cyva system designed for clinical-scale non-viral gene editing of activated and resting T cell therapies, supporting scalable manufacturing workflows beyond research scale.

Quantifiable outcome

  • >90% cell viability with superior cell health and functionality
  • +6 more outcomes

Companies that use CellFE

Customer profile

Segments4 records

Ideal customer profiles2 records

CellFE technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CellFE partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Made ScientificcoreStrategic or Co-development Partner · 13 May 2025Strategic collaboration to generate pilot data on the CellFE High Volume Cyva System for T cell therapies. Made Scientific, a cell therapy CDMO, will conduct pilot-scale studies using CellFE's technology. The partnership aims to validate clinical-scale performance for both activated and resting T cell therapy manufacturing workflows, combining non-viral and viral gene editing approaches.
  • German Cancer Research Center (DKFZ) / TcellTechcoreStrategic or Co-development Partner · 30 April 2025Strategic collaboration combining CellFE's Ryva Mechanoporation System with TcellTech's nanoSMAR gene expression DNA vector platform. Aims to advance personalized cell therapy development by addressing challenges in efficient DNA delivery and maintaining cell viability. Early results demonstrate strong compatibility with promising outcomes in generating stable cell lines expressing CARs or TCRs.
  • Mike RicecoreOthers · 25 June 2024Life science tools veteran appointed to Board of Directors. Previously served as Chairman & CEO at BioLife Solutions. Brings experience in scaling up life sciences tool businesses and deep expertise in CGT space.
  • Georgia Tech Research CorporationcoreStrategic or Co-development Partner · 1 January 2019NIIMBL-funded project collaboration focused on scalable microfluidics for delivery of large transgenes to therapeutic cells. Project involves T-cells and iPSCs for cell therapy manufacturing, aiming to provide the first non-viral platform for transgene transfection from bench to final product using a single protocol.
  • Celgene CorporationminorStrategic or Co-development Partner · 1 January 2019Participant in NIIMBL-funded project (Project Call 2.2) for scalable microfluidics research. Contributing to development of non-viral platform for transgene transfection in cell product manufacturing.
  • Merck & Co., Inc.minorStrategic or Co-development Partner · 1 January 2019Participant in NIIMBL-funded project (Project Call 2.2) for scalable microfluidics research. Contributing to development of GMP-compliant, scalable microfluidic method for transgene delivery.
  • University of IowaminorStrategic or Co-development Partner · 1 January 2019Participant in NIIMBL-funded project for scalable microfluidics research. Part of consortium developing non-viral platform for cell therapy manufacturing.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

CellFE competitors and assessment

Company assessment

Direct peers

  • MaxCyte: MaxCyte is the dominant supplier of flow electroporation technology for non-viral gene delivery in cell therapy development, used by leading CAR-T developers including CRISPR Therapeutics. Directly competes with CellFE's mechanoporation platform as the primary alternative for ex-viral payload delivery into T cells, HSCs, and iPSCs.
  • Celetrix: Celetrix provides electroporation systems specifically tuned for primary and difficult-to-transfect cells including T cells, HSCs, and iPSCs. Competitor in the same gene-delivery tool category as CellFE, with overlapping target customers in cell therapy development.

Emerging players

  • Kytopen: Kytopen develops a Flowfect microfluidic platform for continuous, non-viral cell engineering with a similar design philosophy to CellFE's mechanoporation approach. Both target the same limitation of electroporation (cell stress) using microfluidic-based delivery, making Kytopen a direct emerging competitor.
  • Porton Biologics / Portal Biotechnologies: Portal Biotechnologies develops its own non-viral delivery platform for engineered cell therapy manufacturing, positioning it as an emerging competitor in the same microfluidic/physical delivery category as CellFE.

Broad incumbents

  • Thermo Fisher Scientific (Cell Therapy Systems): Through its Cell Therapy Systems business (including the CTS Rotea counterflow centrifugation system), Thermo Fisher is a broad incumbent in cell therapy manufacturing tools serving the same developers targeted by CellFE. CellFE competes for share within a wider portfolio customer base.
  • Miltenyi Biotec: Miltenyi Biotec offers a comprehensive suite of cell therapy manufacturing platforms, reagents, and instruments (CliniMACS, MACS, electroporation). Serves the same cell therapy developers as CellFE with a broader tools portfolio rather than specialization in delivery technology.
  • Lonza: Lonza is a leading CDMO and process development partner for cell and gene therapy developers. While it doesn't directly compete with CellFE's delivery instrument, its process services touch overlapping buyer personas and could either partner with or compete for cell therapy developer budgets.
  • BioLife Solutions: BioLife Solutions is a public CGT tools company specializing in biopreservation and cell processing consumables (CryoStor, ViaCell, ThawSTAR). Its board connection (Mike Rice is now on CellFE's board) and overlapping customer base create thematic peer comparability in CGT tools.
  • Cytiva: Cytiva (Danaher) provides bioprocessing and cell therapy manufacturing equipment and consumables, including cell processing instrumentation. Adjacent competitor to CellFE in cell therapy manufacturing tooling across upstream and downstream workflows.

Others

  • Akadeum Life Sciences: Akadeum provides buoyancy-based cell separation technology used in cell therapy manufacturing workflows. While not directly competing with CellFE's delivery platform, it serves adjacent process steps within the same cell therapy developer buyer personas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CellFE social profiles

Digital presence

CellFE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CellFE leadership team

Management profile

Number of profiles

Profiles6 records

CellFE funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CellFE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellFE

What does CellFE do?

CellFE develops and sells a microfluidics-based, non-viral cell engineering platform for cell therapy manufacturing. The flagship Ryva Mechanoporation System is a benchtop instrument that uses rapid cellular compression via microfluidic channels with chevron-shaped ridges to deliver gene-editing payloads (including payloads above 10 kb) into T cells, HSCs, and iPSCs. The platform is sold together with single-use consumable Ryva PUPs and complementary workflow kits such as T-Rest for resting T cell CAR-T manufacturing.

Is CellFE a public or private company?

CellFE is a private company. It is classified as venture growth investor backed and is currently operating.

When was CellFE founded?

CellFE was founded in 2020. It employs 11 to 50 people.

Where is CellFE based?

CellFE is headquartered in Alameda, United States, in the North America region.

How does CellFE make money?

Three revenue lines are on record. Ryva System Instruments are the primary driver. The others are ryva PUPs (Processing Units) and T-Rest Kit.

Who are CellFE's main competitors?

Direct peers on record are MaxCyte and Celetrix. Emerging players are Kytopen and Porton Biologics / Portal Biotechnologies. Broad incumbents are Thermo Fisher Scientific (Cell Therapy Systems), Miltenyi Biotec, Lonza, BioLife Solutions and Cytiva. Akadeum Life Sciences is listed as an others.

Does CellFE have an API?

No public API is recorded for CellFE.

What industry is CellFE in?

CellFE's product category is Cell Therapy Manufacturing Equipment. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireMicrofluidics in Oncology Market Trends, Growth Drivers and Regional InsightsThe global microfluidics in oncology market is projected to reach hundreds of millions between 2025 and 2034, driven by demand for early diagnostics and personalized medicine. North America leads, while Asia Pacific is the fastest-growing region, with recent funding rounds from Scope Biosciences, CellFE, and Atrandi Biosciences.Towards HealthcareCell and Gene Therapy Tools and Reagents Top Companies and Strategic InvolvementsThe global cell and gene therapy tools and reagents market reached US$ 11.12 billion in 2025 and is projected to grow to approximately US$ 27.3 billion by 2034, expanding at a CAGR of 10.76%. Notable recent developments include Sartorius Stedim Biotech investing $3 million in Nanotein Technologies for its NanoSpark platform, and Hologen providing $430 million in funding to MeiraGTx for the development of an investigational AAV-GAD gene therapy for Parkinson's disease. Other active developments include product launches by CellFE and Asimov, and a collaboration between CTMC and Syenex to expand lentiviral and retroviral vector manufacturing platforms.PR NewswireCellFE and Made Scientific Announce Strategic Collaboration to Advance Non-viral Gene Editing for T Cell TherapiesCellFE and Made Scientific announced a collaboration to pilot CellFE's non-viral gene editing microfluidics for T cell therapies. The program will test two workflows: activated T cells with combined editing and resting T cells for allogeneic products. Results will be shared in a white paper by October 2025.PR NewswireCellFE® Partners with DKFZ and TcellTech to Advance DNA Vector Genetic Engineering for Cellular TherapiesCellFE announced a partnership with DKFZ and TcellTech to combine its Ryva mechanoporation system with TcellTech's nanoSMAR DNA vector platform for cell therapy. The collaboration aims to enable safer, scalable manufacturing of personalized cell therapies, with early results showing compatibility in generating CAR or TCR-expressing cell lines. Findings will be presented at ASGCT 2025.CellfebiotechCellFE Announces Launch of First-in-Class T-Rest (“Resting T Cell Kit”) for Breakthrough CAR-T Cell Therapy ManufacturingCellFE announced the launch of its T-Rest (Resting T Cell Kit), a first-in-class product designed to optimize gene editing workflows for CAR-T cell therapy manufacturing. The company unveiled the product at Advanced Therapies Week 2025 in Dallas, highlighting data showing that resting T cells edited with T-Rest retain stem cell memory to improve treatment durability and safety. Additionally, CellFE and Avectas initiated a Non-Viral Cell Therapy Working Group during the conference.YahooCellFE® Announces Launch of First-in-Class T-Rest™ ("Resting T Cell Kit") for Breakthrough CAR-T Cell Therapy ManufacturingCellFE announced the launch of T-Rest, a first-in-class resting T cell transfection media for CAR-T cell therapy manufacturing. The kit enables gene editing in non-dividing cells, preserving stem cell memory and reducing chromosomal abnormalities. It will be unveiled at Advanced Therapies Week 2025 in Dallas.PR NewswireCellFE® Announces Launch of First-in-Class T-Rest™ ("Resting T Cell Kit") for Breakthrough CAR-T Cell Therapy ManufacturingCellFE announced the launch of T-Rest, a first-in-class resting T cell transfection media for CAR-T cell therapy manufacturing. The kit enables gene editing in non-dividing cells, preserving stem cell memory and reducing chromosomal abnormalities. It will be unveiled at Advanced Therapies Week 2025 in Dallas.PR NewswireCellFE® and Syenex Collaborate to Advance Cell Engineering with Hybrid Gene Editing WorkflowCellFE and Syenex have announced a collaboration to create a hybrid gene editing workflow that integrates non-viral and viral approaches for cell therapy engineering, with the application note to be unveiled at the JP Morgan Healthcare Conference in San Francisco this January. The workflow aims to address key manufacturing challenges by enabling streamlined workflows that preserve cell viability and functionality during complex, sequential editing processes. This partnership targets allogeneic and autologous cell therapy providers seeking more efficient manufacturing processes to accelerate the development of genetic medicines.